End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease
Am J Kidney Dis
.
2022 May;79(5):754-756.
doi: 10.1053/j.ajkd.2021.09.005.
Epub 2021 Oct 8.
Authors
John C Lieske
1
,
Meaghan A Malley
2
,
Melissa West
2
,
Kim Hollander
3
,
Dawn S Milliner
4
Affiliations
1
Division of Nephrology, Mayo Clinic, Rochester, Minnesota. Electronic address: Lieske.John@mayo.edu.
2
American Society of Nephrology, Washington, DC.
3
Oxalosis and Hyperoxaluria Foundation, New Paltz, New York.
4
Division of Nephrology, Mayo Clinic, Rochester, Minnesota.
PMID:
34634431
DOI:
10.1053/j.ajkd.2021.09.005
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
MeSH terms
Drug Development
Female
Humans
Hyperoxaluria* / drug therapy
Hyperoxaluria, Primary* / drug therapy
Male
Rare Diseases / drug therapy
Grants and funding
R18 FD005283/FD/FDA HHS/United States
R21 TR003174/TR/NCATS NIH HHS/United States
U54 DK083908/DK/NIDDK NIH HHS/United States